Insider Selling: Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Sells 49,407 Shares of Stock

Key Points

• Kiniksa Pharmaceuticals Director Thomas Malley sold 49,407 shares at $32.40 per share, totaling approximately $1.6 million, significantly reducing his ownership in the company by 79.75%.
• After recent trades, Kiniksa's stock price dipped 1.1% to $33.28, though it has fluctuated between a one-year low of $17.82 and a high of $33.98.
• Analysts have increased their price targets for Kiniksa, with Jefferies raising their target from $45.00 to $54.00 and a consensus rating of "Buy" across multiple analysts.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) Director Thomas Malley sold 49,407 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $32.40, for a total value of $1,600,786.80. Following the sale, the director directly owned 12,546 shares in the company, valued at $406,490.40. The trade was a 79.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Thomas Malley also recently made the following trade(s):

• On Wednesday, August 13th, Thomas Malley sold 50,129 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $33.32, for a total value of $1,670,298.28.
• On Thursday, August 14th, Thomas Malley sold 78,233 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $33.09, for a total value of $2,588,729.97.

Kiniksa Pharmaceuticals International Stock Down 1.1%

NASDAQ:KNSA traded down $0.37 during midday trading on Thursday, hitting $33.28. The stock had a trading volume of 474,071 shares, compared to its average volume of 695,957. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $33.98. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of 832.21 and a beta of 0.14. The stock has a 50-day moving average of $29.22 and a 200 day moving average of $24.83.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. The company had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of hedge funds have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after purchasing an additional 532 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after purchasing an additional 568 shares during the last quarter. US Bancorp DE purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at $33,000. Asset Management One Co. Ltd. purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at $41,000. Finally, Wealthquest Corp purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at $42,000. Hedge funds and other institutional investors own 53.95% of the company's stock.

Analysts Set New Price Targets

KNSA has been the topic of a number of analyst reports. Jefferies Financial Group upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Wedbush reaffirmed an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 2nd. Finally, Wells Fargo & Company increased their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.